First Header Logo Second Header Logo

Connection

Lynne Wagenknecht to Obesity

Back to Details
This is a "connection" page, showing publications Lynne Wagenknecht has written about Obesity.
Lynne Wagenknecht
Connection Strength
3.514
Obesity
  1. Samaropoulos XF, Hairston KG, Anderson A, Haffner SM, Lorenzo C, Montez M, Norris JM, Scherzinger AL, Chen YD, Wagenknecht LE. A metabolically healthy obese phenotype in hispanic participants in the IRAS family study. Obesity (Silver Spring). 2013 Nov; 21(11):2303-9.
    View in: PubMed
    Score: 0.274
  2. Il'yasova D, Wang F, Spasojevic I, Base K, D'Agostino RB, Wagenknecht LE. Racial differences in urinary F2-isoprostane levels and the cross-sectional association with BMI. Obesity (Silver Spring). 2012 Oct; 20(10):2147-50.
    View in: PubMed
    Score: 0.257
  3. Il'yasova D, Wang F, Spasojevic I, Base K, D'Agostino RB, Wagenknecht LE. Urinary F2-isoprostanes, obesity, and weight gain in the IRAS cohort. Obesity (Silver Spring). 2012 Sep; 20(9):1915-21.
    View in: PubMed
    Score: 0.244
  4. Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med. 2010 Sep 27; 170(17):1566-75.
    View in: PubMed
    Score: 0.228
  5. Foy CG, Hsu FC, Haffner SM, Norris JM, Rotter JI, Henkin LF, Bryer-Ash M, Chen YD, Wagenknecht LE. Visceral fat and prevalence of hypertension among African Americans and Hispanic Americans: findings from the IRAS family study. Am J Hypertens. 2008 Aug; 21(8):910-6.
    View in: PubMed
    Score: 0.195
  6. Il'yasova D, Morrow JD, Ivanova A, Wagenknecht LE. Epidemiological marker for oxidant status: comparison of the ELISA and the gas chromatography/mass spectrometry assay for urine 2,3-dinor-5,6-dihydro-15-F2t-isoprostane. Ann Epidemiol. 2004 Nov; 14(10):793-7.
    View in: PubMed
    Score: 0.151
  7. Wagenknecht LE, Chao AM, Wadden TA, McCaffery JM, Hayden KM, Laferrère B, Clark JM, Johnson KC, Howard MJ, Yanovski SZ, Wing RR. Impact of COVID-19 on life experiences reported by a diverse cohort of older adults with diabetes and obesity. Obesity (Silver Spring). 2022 06; 30(6):1268-1278.
    View in: PubMed
    Score: 0.127
  8. Belalcazar LM, Ballantyne CM, Lang W, Haffner SM, Rushing J, Schwenke DC, Pi-Sunyer FX, Tracy RP. Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD study. Arterioscler Thromb Vasc Biol. 2011 Jul; 31(7):1689-95.
    View in: PubMed
    Score: 0.118
  9. Olson KL, Neiberg RH, Espeland MA, Johnson KC, Knowler WC, Pi-Sunyer X, Staiano AE, Wagenknecht LE, Wing RR. Waist Circumference Change During Intensive Lifestyle Intervention and Cardiovascular Morbidity and Mortality in the Look AHEAD Trial. Obesity (Silver Spring). 2020 10; 28(10):1902-1911.
    View in: PubMed
    Score: 0.113
  10. Yeh HC, Bantle JP, Cassidy-Begay M, Blackburn G, Bray GA, Byers T, Clark JM, Coday M, Egan C, Espeland MA, Foreyt JP, Garcia K, Goldman V, Gregg EW, Hazuda HP, Hesson L, Hill JO, Horton ES, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Knowler WC, Korytkowski M, Kure A, Lewis CE, Mantzoros C, Meacham M, Montez MG, Nathan DM, Pajewski N, Patricio J, Peters A, Xavier Pi-Sunyer F, Pownall H, Ryan DH, Safford M, Sedjo RL, Steinburg H, Vitolins M, Wadden TA, Wagenknecht LE, Wing RR, Wolff AC, Wyatt H, Yanovski SZ. Intensive Weight Loss Intervention and Cancer Risk in Adults with Type 2 Diabetes: Analysis of the Look AHEAD Randomized Clinical Trial. Obesity (Silver Spring). 2020 09; 28(9):1678-1686.
    View in: PubMed
    Score: 0.113
  11. Gao C, Langefeld CD, Ziegler JT, Taylor KD, Norris JM, Chen YI, Hellwege JN, Guo X, Allison MA, Speliotes EK, Rotter JI, Bowden DW, Wagenknecht LE, Palmer ND. Genome-Wide Study of Subcutaneous and Visceral Adipose Tissue Reveals Novel Sex-Specific Adiposity Loci in Mexican Americans. Obesity (Silver Spring). 2018 01; 26(1):202-212.
    View in: PubMed
    Score: 0.094
  12. Bradshaw PT, Reynolds KR, Wagenknecht LE, Ndumele CE, Stevens J. Incidence of components of metabolic syndrome in the metabolically healthy obese over 9 years follow-up: the Atherosclerosis Risk In Communities study. Int J Obes (Lond). 2018 03; 42(3):295-301.
    View in: PubMed
    Score: 0.093
  13. Yuan M, Hsu FC, Bowden DW, Xu J, Carrie Smith S, Wagenknecht LE, Comeau ME, Divers J, Register TC, Jeffrey Carr J, Langefeld CD, Freedman BI. Relationships between measures of adiposity with subclinical atherosclerosis in patients with type 2 diabetes. Obesity (Silver Spring). 2016 08; 24(8):1810-8.
    View in: PubMed
    Score: 0.085
  14. Gao C, Wang N, Guo X, Ziegler JT, Taylor KD, Xiang AH, Hai Y, Kridel SJ, Nadler JL, Kandeel F, Raffel LJ, Chen YD, Norris JM, Rotter JI, Watanabe RM, Wagenknecht LE, Bowden DW, Speliotes EK, Goodarzi MO, Langefeld CD, Palmer ND. A Comprehensive Analysis of Common and Rare Variants to Identify Adiposity Loci in Hispanic Americans: The IRAS Family Study (IRASFS). PLoS One. 2015; 10(11):e0134649.
    View in: PubMed
    Score: 0.081
  15. Dearborn JL, Schneider AL, Sharrett AR, Mosley TH, Bezerra DC, Knopman DS, Selvin E, Jack CR, Coker LH, Alonso A, Wagenknecht LE, Windham BG, Gottesman RF. Obesity, Insulin Resistance, and Incident Small Vessel Disease on Magnetic Resonance Imaging: Atherosclerosis Risk in Communities Study. Stroke. 2015 Nov; 46(11):3131-6.
    View in: PubMed
    Score: 0.081
  16. Papandonatos GD, Pan Q, Pajewski NM, Delahanty LM, Peter I, Erar B, Ahmad S, Harden M, Chen L, Fontanillas P, Wagenknecht LE, Kahn SE, Wing RR, Jablonski KA, Huggins GS, Knowler WC, Florez JC, McCaffery JM, Franks PW. Genetic Predisposition to Weight Loss and Regain With Lifestyle Intervention: Analyses From the Diabetes Prevention Program and the Look AHEAD Randomized Controlled Trials. Diabetes. 2015 Dec; 64(12):4312-21.
    View in: PubMed
    Score: 0.080
  17. Pownall HJ, Bray GA, Wagenknecht LE, Walkup MP, Heshka S, Hubbard VS, Hill J, Kahn SE, Nathan DM, Schwartz AV, Johnson KC. Changes in body composition over 8 years in a randomized trial of a lifestyle intervention: the look AHEAD study. Obesity (Silver Spring). 2015 Mar; 23(3):565-72.
    View in: PubMed
    Score: 0.077
  18. Peter I, Papandonatos GD, Belalcazar LM, Yang Y, Erar B, Jakicic JM, Unick JL, Balasubramanyam A, Lipkin EW, Delahanty LM, Wagenknecht LE, Wing RR, McCaffery JM, Huggins GS. Genetic modifiers of cardiorespiratory fitness response to lifestyle intervention. Med Sci Sports Exerc. 2014 Feb; 46(2):302-11.
    View in: PubMed
    Score: 0.072
  19. Huggins GS, Papandonatos GD, Erar B, Belalcazar LM, Brautbar A, Ballantyne C, Kitabchi AE, Wagenknecht LE, Knowler WC, Pownall HJ, Wing RR, Peter I, McCaffery JM. Do genetic modifiers of high-density lipoprotein cholesterol and triglyceride levels also modify their response to a lifestyle intervention in the setting of obesity and type-2 diabetes mellitus?: The Action for Health in Diabetes (Look AHEAD) study. Circ Cardiovasc Genet. 2013 Aug; 6(4):391-9.
    View in: PubMed
    Score: 0.069
  20. McCaffery JM, Papandonatos GD, Huggins GS, Peter I, Kahn SE, Knowler WC, Hudnall GE, Lipkin EW, Kitabchi AE, Wagenknecht LE, Wing RR. FTO predicts weight regain in the Look AHEAD clinical trial. Int J Obes (Lond). 2013 Dec; 37(12):1545-52.
    View in: PubMed
    Score: 0.068
  21. Unick JL, Beavers D, Bond DS, Clark JM, Jakicic JM, Kitabchi AE, Knowler WC, Wadden TA, Wagenknecht LE, Wing RR. The long-term effectiveness of a lifestyle intervention in severely obese individuals. Am J Med. 2013 Mar; 126(3):236-42, 242.e1-2.
    View in: PubMed
    Score: 0.067
  22. McCaffery JM, Papandonatos GD, Peter I, Huggins GS, Raynor HA, Delahanty LM, Cheskin LJ, Balasubramanyam A, Wagenknecht LE, Wing RR. Obesity susceptibility loci and dietary intake in the Look AHEAD Trial. Am J Clin Nutr. 2012 Jun; 95(6):1477-86.
    View in: PubMed
    Score: 0.063
  23. Peter I, McCaffery JM, Kelley-Hedgepeth A, Hakonarson H, Reis S, Wagenknecht LE, Kopin AS, Huggins GS. Association of type 2 diabetes susceptibility loci with one-year weight loss in the look AHEAD clinical trial. Obesity (Silver Spring). 2012 Aug; 20(8):1675-82.
    View in: PubMed
    Score: 0.063
  24. Hester JM, Wing MR, Li J, Palmer ND, Xu J, Hicks PJ, Roh BH, Norris JM, Wagenknecht LE, Langefeld CD, Freedman BI, Bowden DW, Ng MC. Implication of European-derived adiposity loci in African Americans. Int J Obes (Lond). 2012 Mar; 36(3):465-73.
    View in: PubMed
    Score: 0.060
  25. Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, Hill JO, Brancati FL, Peters A, Wagenknecht L. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011 Jul; 34(7):1481-6.
    View in: PubMed
    Score: 0.060
  26. Wing MR, Ziegler JM, Langefeld CD, Roh BH, Palmer ND, Mayer-Davis EJ, Rewers MJ, Haffner SM, Wagenknecht LE, Bowden DW. Analysis of FTO gene variants with obesity and glucose homeostasis measures in the multiethnic Insulin Resistance Atherosclerosis Study cohort. Int J Obes (Lond). 2011 Sep; 35(9):1173-82.
    View in: PubMed
    Score: 0.058
  27. Foy CG, Lewis CE, Hairston KG, Miller GD, Lang W, Jakicic JM, Rejeski WJ, Ribisl PM, Walkup MP, Wagenknecht LE. Intensive lifestyle intervention improves physical function among obese adults with knee pain: findings from the Look AHEAD trial. Obesity (Silver Spring). 2011 Jan; 19(1):83-93.
    View in: PubMed
    Score: 0.056
  28. Hanley AJ, Wagenknecht LE. Abdominal adiposity and diabetes risk: the importance of precise measures and longitudinal studies. Diabetes. 2008 May; 57(5):1153-5.
    View in: PubMed
    Score: 0.048
  29. Bray G, Gregg E, Haffner S, Pi-Sunyer XF, WagenKnecht LE, Walkup M, Wing R. Baseline characteristics of the randomised cohort from the Look AHEAD (Action for Health in Diabetes) study. Diab Vasc Dis Res. 2006 Dec; 3(3):202-15.
    View in: PubMed
    Score: 0.044
  30. Wadden TA, West DS, Delahanty L, Jakicic J, Rejeski J, Williamson D, Berkowitz RI, Kelley DE, Tomchee C, Hill JO, Kumanyika S. The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. Obesity (Silver Spring). 2006 May; 14(5):737-52.
    View in: PubMed
    Score: 0.042
  31. Agarwal M, Selvan V, Freedman BI, Liu Y, Wagenknecht LE. The relationship between albuminuria and hormone therapy in postmenopausal women. Am J Kidney Dis. 2005 Jun; 45(6):1019-25.
    View in: PubMed
    Score: 0.039
  32. Karter AJ, D'Agostino RB, Mayer-Davis EJ, Wagenknecht LE, Hanley AJ, Hamman RF, Bergman R, Saad MF, Haffner SM. Abdominal obesity predicts declining insulin sensitivity in non-obese normoglycaemics: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Obes Metab. 2005 May; 7(3):230-8.
    View in: PubMed
    Score: 0.039
  33. Haffner SM, D'Agostino R, Festa A, Bergman RN, Mykkänen L, Karter A, Saad MF, Wagenknecht LE. Low insulin sensitivity (S(i) = 0) in diabetic and nondiabetic subjects in the insulin resistance atherosclerosis study: is it associated with components of the metabolic syndrome and nontraditional risk factors? Diabetes Care. 2003 Oct; 26(10):2796-803.
    View in: PubMed
    Score: 0.035
  34. Bancks MP, Lovato J, Balasubramanyam A, Coday M, Johnson KC, Munshi M, Rebello C, Wagenknecht LE, Espeland MA. Association of Type 2 Diabetes Subgroups With Cognitive Status Without Modification From Lifestyle Intervention. J Clin Endocrinol Metab. 2023 May 17; 108(6):e334-e342.
    View in: PubMed
    Score: 0.034
  35. Gregg EW, Lin J, Bardenheier B, Chen H, Rejeski WJ, Zhuo X, Hergenroeder AL, Kritchevsky SB, Peters AL, Wagenknecht LE, Ip EH, Espeland MA. Impact of Intensive Lifestyle Intervention on Disability-Free Life Expectancy: The Look AHEAD Study. Diabetes Care. 2018 05; 41(5):1040-1048.
    View in: PubMed
    Score: 0.024
  36. Wing RR, Espeland MA, Hazuda HP, Knowler WC, Wadden T. Association of Weight Loss Maintenance and Weight Regain on 4-Year Changes in CVD Risk Factors: the Action for Health in Diabetes (Look AHEAD) Clinical Trial. Diabetes Care. 2016 Aug; 39(8):1345-55.
    View in: PubMed
    Score: 0.021
  37. McCaffery JM, Papandonatos GD, Faulconbridge LF, Erar B, Peter I, Wagenknecht LE, Pajewski NM, Anderson A, Wadden TA, Wing RR. Genetic Predictors of Depressive Symptoms in the Look AHEAD Trial. Psychosom Med. 2015 Nov-Dec; 77(9):982-92.
    View in: PubMed
    Score: 0.020
  38. Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, Espeland MA, Evans M, Foreyt JP, Ghazarian S, Gregg EW, Harrison B, Hazuda HP, Hill JO, Horton ES, Hubbard VS, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montez MG, Murillo A, Nathan DM, Patricio J, Peters A, Pi-Sunyer X, Pownall H, Reboussin D, Regensteiner JG, Rickman AD, Ryan DH, Safford M, Wadden TA, Wagenknecht LE, West DS, Williamson DF, Yanovski SZ. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013 Jul 11; 369(2):145-54.
    View in: PubMed
    Score: 0.017
  39. Register TC, Divers J, Bowden DW, Carr JJ, Lenchik L, Wagenknecht LE, Hightower RC, Xu J, Smith SC, Hruska KA, Langefeld CD, Freedman BI. Relationships between serum adiponectin and bone density, adiposity and calcified atherosclerotic plaque in the African American-Diabetes Heart Study. J Clin Endocrinol Metab. 2013 May; 98(5):1916-22.
    View in: PubMed
    Score: 0.017
  40. Bertoni AG, Wagenknecht LE, Kitzman DW, Marcovina SM, Rushing JT, Espeland MA. Impact of the look AHEAD intervention on NT-pro brain natriuretic peptide in overweight and obese adults with diabetes. Obesity (Silver Spring). 2012 Jul; 20(7):1511-8.
    View in: PubMed
    Score: 0.015
  41. Sibbel SP, Talbert ME, Bowden DW, Haffner SM, Taylor KD, Chen YD, Wagenknecht LE, Langefeld CD, Norris JM. RGS6 variants are associated with dietary fat intake in Hispanics: the IRAS Family Study. Obesity (Silver Spring). 2011 Jul; 19(7):1433-8.
    View in: PubMed
    Score: 0.015
  42. Masters RC, Liese AD, Haffner SM, Wagenknecht LE, Hanley AJ. Whole and refined grain intakes are related to inflammatory protein concentrations in human plasma. J Nutr. 2010 Mar; 140(3):587-94.
    View in: PubMed
    Score: 0.014
  43. MacKay MF, Haffner SM, Wagenknecht LE, D'Agostino RB, Hanley AJ. Prediction of type 2 diabetes using alternate anthropometric measures in a multi-ethnic cohort: the insulin resistance atherosclerosis study. Diabetes Care. 2009 May; 32(5):956-8.
    View in: PubMed
    Score: 0.013
  44. Espeland MA, Regensteiner JG, Jaramillo SA, Gregg E, Knowler WC, Wagenknecht LE, Bahnson J, Haffner S, Hill J, Hiatt WR. Measurement characteristics of the ankle-brachial index: results from the Action for Health in Diabetes study. Vasc Med. 2008 Aug; 13(3):225-33.
    View in: PubMed
    Score: 0.012
  45. Wheeler GL, Shi R, Beck SR, Langefeld CD, Lenchik L, Wagenknecht LE, Freedman BI, Rich SS, Bowden DW, Chen MY, Carr JJ. Pericardial and visceral adipose tissues measured volumetrically with computed tomography are highly associated in type 2 diabetic families. Invest Radiol. 2005 Feb; 40(2):97-101.
    View in: PubMed
    Score: 0.010
  46. Williams K, Sniderman AD, Sattar N, D'Agostino R, Wagenknecht LE, Haffner SM. Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2003 Nov 11; 108(19):2312-6.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.